TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04729322
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05991908
Drug: Fludarabine, busulfan and melphalan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
Study: NCT05991908
Drug: Fludarabine and Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
Study: NCT06024408
Drug: ALN-PNP
Normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
Study: NCT06784947
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.
Study: NCT06784947
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
Study: NCT06784947
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.
Study: NCT06045351
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day
Study: NCT06734884
Drug: Benralizumab 30 MG/ML [Fasenra]
Normalized name: benralizumab 30 MG/ML [Fasenra]
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection 30 mg at day 2, week 4 and week 8.
Study: NCT06734884
Drug: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection at day 2, week 4 and week 8
Study: NCT06749860
Drug: Disitamab Vedotin + tislelizumab + bevacizumab
Normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use.
Study: NCT06760858
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles.
Study: NCT06760858
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOX: S-1 dosage based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 3 cycles.
Study: NCT06762158
Drug: neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
Study: NCT06762158
Drug: adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
Study: NCT06762223
Drug: Henagliflozin 10 mg daily
Normalized name: Henagliflozin
DrugBank: Henagliflozin (DB11939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.
Study: NCT06762223
Drug: Metformin 1700 mg daily
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
Study: NCT06762314
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
Study: NCT06762314
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days
Study: NCT06762314
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
Study: NCT06773156
Drug: Adebrelimab + Apatinib
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: Administered by intravenous infusion at a fixed dose of 1200 mg. The infusion should be completed within 30-60 minutes, with a maximum duration of 2 hours. The first dose is given on Day 1, with subsequent doses repeated every 3 weeks. Dose adjustments (either up or down) are not allowed during the study. A maximum delay of 9 weeks for treatment is allowed, or treatment may be terminated.~Apatinib: 250 mg, taken orally after meals, once daily, continuously. The investigator may temporarily pause the dose or adjust the administration schedule based on symptomatic treatment, such as changing to an every-other-day (qod) schedule or a 5-day-on, 2-day-off regimen. Once toxicity resolves, treatment may resume at the original dose.~The combined treatment of Adebrelimab + Apatinib for consolidation therapy should not exceed 24 months in total.
Study: NCT06760546
Drug: Setmelanotide
Normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution for daily subcutaneous injection
Study: NCT06764238
Drug: Blinatumomab (Group A)
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
Study: NCT06764238
Drug: Blinatumomab (Group B)
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
Study: NCT04777851
Drug: Regorafenib in combination with pembrolizumab
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
Study: NCT06779149
Drug: Lemborexant
Normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants assigned to this group will be prescribed 5 to 10 mg of lemborexant to be taken at bedtime in 5 mg capsules. Lemborexant (Dayvigo) is a Dual Orexin Receptor Antagonist approved by Health Canada for the treatment of adult with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
Study: NCT06780579
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 10 mg BLV will be administered via subcutaneous injection
Study: NCT06790784
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment must be initiated on the day of randomization with one faricumab injection. The remainder of the randomized treatment includes 2 additional injections every 4-weeks. Injections must be completed within 90 days of randomization.
Study: NCT04858139
Drug: Lactate
Normalized name: Lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
Study: NCT05077904
Drug: Staccato alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period.
Study: NCT04444440
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoroquinolone antibiotic.
Study: NCT04729114
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose
Study: NCT04729114
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral dose
Study: NCT04729114
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsule
Study: NCT04665739
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04665739
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04322305
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
Study: NCT04643002
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Study: NCT04643002
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT04643002
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Study: NCT04643002
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT04643002
Drug: Pegenzileukin
Normalized name: Pegenzileukin
DrugBank: Pegenzileukin (DB17495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT04643002
Drug: Belumosudil
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet; route of administration: oral
Study: NCT04643002
Drug: Evorpacept
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT06798025
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were treated with a peri-punctual injection of Triamcinolone acetonide.
Study: NCT06048380
Drug: Ripasudil
Normalized name: ripasudil
DrugBank: Ripasudil (DB13165)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil.
Study: NCT05977322
Drug: 68Ga-FF58
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection
Study: NCT05977322
Drug: 177Lu-FF58
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection/infusion
Study: NCT05966064
Drug: Denosumab 120 Mg/1.7 Ml Inj
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
Study: NCT05836025
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/week of rapamycin orally for 12 weeks
Study: NCT05063786
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg oral once daily.
Study: NCT05063786
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
Study: NCT05063786
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
Study: NCT05063786
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
Study: NCT05838846
Drug: Inhaled Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
Study: NCT05838846
Drug: IV Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive intravenous milrinone infusion at dosage of 0.3 - 0.75 mcg/kg/min with loading dose of 50 mcg/kg over 10 min. After cross clamp off and temperature of 32 degree, Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
Study: NCT06384976
Drug: Anti-CD20 mAB
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-CD20 mAB
Study: NCT04996134
Drug: Domperidone Oral Product
Normalized name: domperidone Oral Product
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-30 mg of oral domperidone administered QID.
Study: NCT06748651
Drug: Allocetra
Normalized name: Allocetra
DrugBank: Allocetra (DB16424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Allocetra performed once on Day 1 of the study
Study: NCT05198960
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
Study: NCT06696768
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05495464
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT05495464
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05495464
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT06293651
Drug: DA-4505
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
Study: NCT06293651
Drug: DA-4505 + Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
Study: NCT05050084
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05050084
Drug: Buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05050084
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05050084
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection
Study: NCT05050084
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05050084
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection
Study: NCT05050084
Drug: Histrelin
Normalized name: Histrelin
DrugBank: Histrelin (DB06788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant
Study: NCT05050084
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05050084
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT05050084
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection
Study: NCT06597201
Drug: amino acid (15) peritoneal dialysis solution
Normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
Study: NCT06593392
Drug: Difelikefalin
Normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
Study: NCT06321523
Drug: Tafamidis 61 milligrams
Normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafamidis 61mg as provided in real-world practice
Study: NCT06617923
Drug: Senaparib
Normalized name: Senaparib
DrugBank: Senaparib (DB17163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
Study: NCT06617923
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
Study: NCT06743581
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg administered intravenously on day 1
Study: NCT06743581
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab 600 mg administered subcutaneously on day 1
Study: NCT05338632
Drug: Naloxone Hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone 0.4mg/mL
Study: NCT05338632
Drug: Nalmefene HCl injection
Normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nalmefene 1 ng/mL